JPH0411558B2 - - Google Patents
Info
- Publication number
- JPH0411558B2 JPH0411558B2 JP57046179A JP4617982A JPH0411558B2 JP H0411558 B2 JPH0411558 B2 JP H0411558B2 JP 57046179 A JP57046179 A JP 57046179A JP 4617982 A JP4617982 A JP 4617982A JP H0411558 B2 JPH0411558 B2 JP H0411558B2
- Authority
- JP
- Japan
- Prior art keywords
- methylene
- formula
- propionic acid
- solution
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 17
- -1 propionic acid lactone Chemical class 0.000 claims description 16
- 235000019260 propionic acid Nutrition 0.000 claims description 15
- 150000002596 lactones Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- BWILYWWHXDGKQA-UHFFFAOYSA-M potassium propanoate Chemical compound [K+].CCC([O-])=O BWILYWWHXDGKQA-UHFFFAOYSA-M 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 229940083712 aldosterone antagonist Drugs 0.000 abstract description 2
- 239000002170 aldosterone antagonist Substances 0.000 abstract description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 abstract 1
- 229940119740 deoxycorticosterone Drugs 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 210000000172 cytosol Anatomy 0.000 description 10
- 238000006073 displacement reaction Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229960003387 progesterone Drugs 0.000 description 8
- 239000000186 progesterone Substances 0.000 description 8
- 235000012239 silicon dioxide Nutrition 0.000 description 8
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229960003473 androstanolone Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000006356 dehydrogenation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex⢠Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- ZOGHDTBRWUEJDP-UHFFFAOYSA-N diethylalumanylium;cyanide Chemical compound N#[C-].CC[Al+]CC ZOGHDTBRWUEJDP-UHFFFAOYSA-N 0.000 description 2
- 231100000673 doseâresponse relationship Toxicity 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 244000062940 Leptospermum flavescens Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000011719 Nomada opaca Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000014034 Transcortin Human genes 0.000 description 1
- 108010011095 Transcortin Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PNZVFASWDSMJER-UHFFFAOYSA-N acetic acid;lead Chemical compound [Pb].CC(O)=O PNZVFASWDSMJER-UHFFFAOYSA-N 0.000 description 1
- LVAMVZXECCXUGI-UHFFFAOYSA-N acetic acid;thallium Chemical compound [Tl].CC(O)=O LVAMVZXECCXUGI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical group CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- YGHUUVGIRWMJGE-UHFFFAOYSA-N chlorodimethylsilane Chemical compound C[SiH](C)Cl YGHUUVGIRWMJGE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
æ¬çºæã¯ãäžè¬åŒïŒïŒïŒ
åŒäžãR1ã¯æ°ŽçŽ åååã¯ã¡ãã«åºã衚ããã
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯
ãåŒãåºåã¯
ãåŒãåºã衚ãããã¯ã«
ã«ããã«åºã衚ããããã€ç¬¬ïŒåã³ç¬¬ïŒã®ççŽ å
åéã®çµåã¯ã飜åãããŠãããåã¯äºéçµåã§
ããããããã¯ç¬¬ïŒåã³ç¬¬ïŒã®ççŽ ååéã®çµå
ãåçµåã§ããå Žåã ã¯
åéã®çµåã¯ã飜åãããŠãããåã¯äºéçµåã§
ããããããã¯ç¬¬ïŒåã³ç¬¬ïŒã®ççŽ ååéã®çµå
ãåçµåã§ããå Žåã ã¯
ãåŒãåºã衚ããã
ã¯
ãåŒãåºã衚ãããã§ç€ºãããæ°èŠ
ã®7αâã¢ã«ã³ãã·ã«ã«ããã«â15βïŒ16βâã¡ã
ã¬ã³âïŒâã¢ã³ããã¹ãã³ååç©ã«é¢ããã æ¬çºæã«ããååç©ã¯ãéèŠãªè¬çäœçšãæã
ãã該ååç©ã¯ããªããããã¢ã«ãã¹ããã³âæ®
æè³ªã®åã®å©å°¿å€ã§ãããããªãã¡ããã¯ããã
ãªãŠã âåã³ã«ãªãŠã é¢è±ã«å¯ŸããŠãã¹ãªãã·ã³
ã«ãã³ã¹ããã³ã®åäœçšã瀺ããæ¬çºæã«ããå
åç©ã¯ããã«ãã³ïŒHollmannïŒã®è©Šéšåœ¢åŒïŒG.
Hollmannä»ãâTubulašre Wirkungen und
renale Elimination von Spirolactonenâã
NaunynâSchmidebergs Arch.Exp.Path.
Pharmak.第247å·»ã1964幎ã第419é ïŒP.Marxã
âRenale Wirkungen des ïœâAldosterons und
seines Antagonisten SpironolactonsâãDiss.
Med.Fak.FU Berlinã1966幎ïŒã§ãã®äœçšã®ç¹
ã§å ¬ç¥ã®ã¹ãããã©ã¯ãã³ãããé©ç°çã«åè¶ã
ãŠããããšã蚌æãããã æŽã«ãæ¬çºæã¯ãäžè¬åŒïŒïŒïŒ åŒäžãR1ã¯æ°ŽçŽ åååã¯ã¡ãã«åºã衚ããã
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯
ã¬ã³âïŒâã¢ã³ããã¹ãã³ååç©ã«é¢ããã æ¬çºæã«ããååç©ã¯ãéèŠãªè¬çäœçšãæã
ãã該ååç©ã¯ããªããããã¢ã«ãã¹ããã³âæ®
æè³ªã®åã®å©å°¿å€ã§ãããããªãã¡ããã¯ããã
ãªãŠã âåã³ã«ãªãŠã é¢è±ã«å¯ŸããŠãã¹ãªãã·ã³
ã«ãã³ã¹ããã³ã®åäœçšã瀺ããæ¬çºæã«ããå
åç©ã¯ããã«ãã³ïŒHollmannïŒã®è©Šéšåœ¢åŒïŒG.
Hollmannä»ãâTubulašre Wirkungen und
renale Elimination von Spirolactonenâã
NaunynâSchmidebergs Arch.Exp.Path.
Pharmak.第247å·»ã1964幎ã第419é ïŒP.Marxã
âRenale Wirkungen des ïœâAldosterons und
seines Antagonisten SpironolactonsâãDiss.
Med.Fak.FU Berlinã1966幎ïŒã§ãã®äœçšã®ç¹
ã§å ¬ç¥ã®ã¹ãããã©ã¯ãã³ãããé©ç°çã«åè¶ã
ãŠããããšã蚌æãããã æŽã«ãæ¬çºæã¯ãäžè¬åŒïŒïŒïŒ åŒäžãR1ã¯æ°ŽçŽ åååã¯ã¡ãã«åºã衚ããã
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯
ãåŒãåºåã¯
ãåŒãåºã衚ãããã¯ã«
ã«ããã«åºã衚ããããã€ç¬¬ïŒåã³ç¬¬ïŒã®ççŽ å
åéã®çµåã¯ã飜åãããŠãããåã¯äºéçµåã§
ãããã§ç€ºããã7αâã¢ã«ã³ãã·ã«ã«ããã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³åå
ç©ã®è£œé æ³ã«é¢ãããã®æ¹æ³ã¯ãèªäœå ¬ç¥ã®æ¹æ³
ã§ãäžè¬åŒïŒïŒïŒ ãåŒäžãR1ã¯åèšã®ãã®ã衚ãããã§ç€ºããã
ååç©ãåå¿ãããŠäœçŽã¢ã«ãã«âãšã¹ãã«ã«å€
ããå Žåã«ãã€ãŠã¯â³1âäºéçµåãå°å ¥ãå
ã³ïŒåã¯ã©ã¯ãã³ç°ãçžåœããããããªã³é žâã«
ãªãŠã å¡©ã«éç°ããããšãç¹åŸŽãšããã åŒïŒïŒã®7αâã«ã«ããã·ã«ååç©ã®ãšã¹ã
ã«åã¯ãèªäœå ¬ç¥ã®æ¹æ³ã«ãããã«ã«ãã³é žãšã
ãžã¢ãŸã¢ã«ã«ã³ãäŸãã°ãžã¢ãŸã¡ã¿ã³åã¯ãžã¢ãŸ
ãšã¿ã³ãšããé©åœãªæº¶å€äžãäŸãã°ãžãšãã«ãšãŒ
ãã«ãããã©ããããã©ã³ãããã¯ãžãªããµã³å
ã¯ãããæº¶å€ã®æ··åç©äžã§ïŒâã25âãæå©ã«ïŒ
âãïŒâã®æž©åºŠã§åå¿ãããåŒç¶ãéå°ã®ãžã¢ãŸ
ã¢ã«ã«ã³ãææ©é žãäŸãã°æ°·é ¢é žåã¯é ç³é žãæ·»
å ããããšã«ãã€ãŠåè§£ãããã€ãã®æº¶æ¶²ããç
空äžã§æº¶å€ãé€å»ããããšã«ããè¡ãªããããã
ã®ãšã¹ãã«åã¯ãåœæ¥è ã«å ¬ç¥ã®æ¹æ³ã«ããåŒ
ïŒïŒã®ã«ã«ãã³é žãšãäŸãã°ã¯ãã«è»é žããã«
âåã¯ã€ãœããã«âãšã¹ãã«ã®ãããªã¯ãã«è»é ž
âã¢ã«ãã«ãšã¹ãã«ãšããé©åœãªæº¶å€äžãäŸãã°
ããã©ããããã©ã³åã¯ãžãªããµã³äžã§HClâå
容察ãšããŠã®äŸãã°ããªãšãã«ã¢ãã³ã®ãããªïŒ
çŽã¢ãã³ã®ååšäžã§ïŒâã20âãæå©ã«ïŒâãïŒ
âã®æž©åºŠã§åå¿ãããäžè¬åŒïŒïŒïŒ ãåŒäžãR1ãåã³ïŒ¹ã¯ããããåèšã®ãã®ã
衚ãããã§ç€ºãããæ··åç¡æ°Žç©ã«å€ããããšã«ã
ãã宿œããããšãã§ããã åŸåŠçããããã«ã¯ãïŒçŽã¢ãã³âå¡©é žå¡©ã®åœ¢
æãããæ²æ®¿ç©ãå¥ããæ¶²ããæº¶å€ãé€å»
ãããã®éã«åŒïŒïŒã®æ··åç¡æ°Žç©ã¯ç²è£œçæç©
ãšããŠåŸãããã äžè¬åŒïŒïŒã®ææã®ãšã¹ãã«ãåŸãããã«
ã¯ãåŒïŒïŒã®ååç©ãã¢ã«ã³ãŒã«R2âOHïŒäœ
ããR2ã¯åèšã®ãã®ã衚ããïŒã«æº¶è§£ãããã®
溶液ã24ã72æéãæå©ã«48æé沞隰å ç±ããã
ã®åŸã«æº¶å€ãçå»ããåŒïŒïŒã®ååç©ãåé¢ã
ãã â³1âäºéçµåã®å°å ¥ã¯ãèªäœå ¬ç¥ã®æ¹æ³ã«ã
ãè¡ãªãããååŠçåã¯åŸ®çç©åŠçæ¹æ³ã§è¡ãªã
ããšãã§ãããïŒïŒïŒâè±æ°ŽçŽ åã«é©ããååŠç
è±æ°ŽçŽ åå€ã¯ãäŸãã°äºé žåã»ã¬ã³ãïŒïŒïŒâãž
ã¯ãã«âïŒïŒïŒâãžã·ã¢ããã³ãŸããã³ãã¯ãã©
ãã«ãäžé ¢é žã¿ãªãŠã åã¯åé ¢é žéã§ããã ïŒïŒïŒâè±æ°ŽçŽ åã«é©ãã埮çç©ã¯ãäŸãã°å
è£èãæ®ã«äŸãã°åäžATCC6946ã®ãããªã¢ã«ã¹
ããã¯ã¿ãŒå±ïŒArthrobacterïŒã®ãã®ïŒäŸãã°
ããã«ã¹ã»ã¬ã³ãã¹ïŒB.lentusïŒATCC13805å
ã³ããã«ã¹ã»ã¹ããšãªã¯ã¹ïŒB.sphaericusïŒ
ATCC7055ã®ãããªããã«ã¹å±ïŒBacillusïŒã®ã
ã®ïŒäŸãã°ç·è¿èïŒP.aeruginosaïŒIFO3505ã®ã
ããªã·ãŠãŒãã¢ãã¹å±ïŒPseudmonasïŒã®ãã®ïŒ
äŸãã°ãã©ããã¯ããªãŠã ã»ãã©ããã»ã³ã¹ïŒF.
flavescensïŒIFO3058ã®ãããªãã©ããã¯ããªãŠ
ã å±ïŒFlavobacteriumïŒã®ãã®ïŒäŸãã°ã©ã¯ã
ããã«ã¹ã»ãã¬ãã¹ïŒL.brevisïŒIFO3345ã®ãã
ãªã©ã¯ãããã«ã¹å±ïŒLactobacillusïŒãªãã³ã«
äŸãã°ãã«ã«ãžã¢ã»ãªãã«ïŒN.opacaïŒ
ATCC4276ã®ãããªãã«ã«ãžã¢å±ïŒNocardiaïŒ
ã®ãã®ã§ããã ïŒïŒïŒâè±æ°ŽçŽ åã¯ãååŠçã«å®æœããã®ã奜
ãŸããããã®ããã«ã¯ãïŒïŒïŒâãžãããã¹ãã
ã€ããé©åœãªæº¶å€äžã§è±æ°ŽçŽ åå€ãšäžç·ã«é·æé
å ç±ãããé©åœãªæº¶å€ã¯ãäŸãã°ãžãªããµã³ã第
äžãã¿ããŒã«ãããã©ããããã©ã³ããã«ãªãŒ
ã«ããã³ãŸãŒã«ãªããã¯ãããæº¶å€ã®æ··åç©ã§ã
ãã åå¿ã¯ãæ°æéåŸã«çµçµãããåå¿ã¯èå±€ã¯ã
ããã°ã©ãã€ãŒã«ãã€ãŠè¡ãªãã®ãæãŸãããå
å¿æ··åç©ã¯ãåºçºç©è³ªãåå¿ããŠããå Žåã«åŸåŠ
çãããã ã©ã¯ãã³ç°ã®å Žåã«ãã€ãŠã¯åŒç¶ãéç°ã¯ãå
æ§ã«èªäœå ¬ç¥ã®æ¹æ³ã«ããè¡ãªãããããã®ãã
ã«ã¯ãã©ã¯ãã³ãåžèæ§ã«ãªæ¶²ãšäžç·ã«å ç±ãã
ãã®éã«ïŒâ眮æããããªã³é žã®ã«ãªãŠã å¡©ã¯åœ¢
æãããã åå¿ã®çµçµåŸããã®åå¿æ··åç©ã¯ãåžžæ³ã§ãäŸ
ãã°æ²æ®¿ç©ãæœåºç©ãåçµæ¶æ³åã³ïŒåã¯ã«ã©ã
ã¯ãããã°ã©ãã€ãŒæ³ã«ãã€ãŠåŸåŠçãããã éå§å€çµæç©ã®è£œé (A) ïŒâïŒ7αâã«ã«ããã·â17βâããããã·â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢ã³
ããã¹ãã³â17αâã€ã«ïŒâããããªã³é žã©ã¯
ãã³ïŒ ïŒ ïŒâïŒ17βâããããã·â15βïŒ16βâã¡ã
ã¬ã³âïŒâãªããœâïŒïŒïŒâã¢ã³ããã¹ã¿â
ãžãšã³â17αâã€ã«ïŒâããããªã³é žã©ã¯ã
ã³ïŒè£œé ã¯è¥¿ãã€ãåœç¹èš±å ¬éå ¬å ±ç¬¬
2652761å·ãåç §ïŒ5.3ïœãç¡æ°Žããã©ããã
ãã©ã³100mlã«æº¶è§£ãããã®æº¶æ¶²ã«ã¢ã«ãŽã³
é°å²æ°äžã§ãã«ãªãŒã«äžã®ã·ã¢ã³åãžãšãã«
ã¢ã«ãããŠã ã®ïŒã¢ã«ã®æº¶æ¶²ã30mlãæ·»å
ãããã®æº¶æ¶²ãéæµäžã§30åéç ®æ²žããå·åŽ
ãã1nèæ§ãœãŒãæ¶²100mläžã«å ããããžã¯
ãã«ã¡ã¿ã³ã§ã®æœåºåŸããã®æº¶æ¶²ã20ïŒ ç¡«é ž
ã§æŽæµããæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããã€ç空äžã§æ¿çž®ãããç²è£œçæç©
ãçªçŽ ã²ã«ã§ãããµã³ïŒã¢ã»ãã³ã§ã¯ããã
ã°ã©ãã€ãŒåŠçããããšã«ãã€ãŠãèç¹238
âã241âïŒâïŒ7αâã·ã¢ãâ17βâãããã
ã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒ
âã¢ã³ããã¹ãã³â17αâã€ã«ïŒâããããª
ã³é žã©ã¯ãã³ïŒïœãåŸãããã αDïŒ68°ãUVïŒÎµ235ïŒ14400ã IRïŒ2250ã1770ã1680ã1640cm-1ã ïŒ ïŒâïŒ7αâã·ã¢ãâ17βâããããã·â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒâããããªã³é ž
ã©ã¯ãã³5.0ïœãç¡æ°Žããã©ããããã©ã³300
mlã«æº¶è§£ãããã®æº¶æ¶²ãâ70âã«å·åŽããã
ãã®æº¶æ¶²ã«ãã«ãªãŒã«äžã®1.2ã¢ã«ã®æ°ŽçŽ å
ã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²35mlãæ»Žå
ãããã®æº¶æ¶²ãâ70âã§ïŒæéããã«æ¹æ
ãã飜åã¯ãšã³é žæº¶æ¶²200mlã§åè§£ãããžã¯
ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµããç¡«é ž
ãããªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ã
ããåŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ã
ã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠ
çããããšã«ãã€ãŠç²Ÿè£œãããèç¹226âã
228âã®3βïŒ5â²âãžããããã·â15βïŒ16βâ
ã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³âã17ïŒÎ²â
1â²ãã¹ããâ2â²ãâãã«ããããã©ã³â7αâ
ã«ã«ããããªã«3.9ïœãåŸãããã IRïŒ3650ã3500ã2250ã1710cm-1ã ïŒ 3βïŒ5â²âãžããããã·â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³âã17ïŒÎ²â1â²ïŒã¹ã
ãâ2â²ãâãã«ããããã©ã³â7αâã«ã«ãã
ããªã«3.65ïœããžã¡ãã«ãã«ã ã¢ãã75mlã«
溶解ãããã®æº¶æ¶²ãã€ãããŸãŒã«2.25ïœåã³
第äžããã«âãžã¡ãã«ã·ãªã«ã¯ããªã4.05ïœ
ãšäžç·ã«å®€æž©ã§ïŒæéæ¹æããæ°·æ°ŽïŒäžã«
å ããæ²æ®¿ããæ²æ®¿ç©ãå¥ãããžã¯ãã«ã¡
ã¿ã³ã«åŒåããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãã
ãã€ç空äžã§æ¿çž®ãããåŸãããç²è£œçæç©
ãçªé žã²ã«ã§ãããµã³ïŒé ¢é žãšã¹ãã«ã§ç²Ÿè£œ
ãããïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«
âã·ãªã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒ
âã¢ã³ããã¹ãã³âãïŒ17βâ1â²ïŒâã¹ããâ
2â²ããã«ããããã©ã³â7αâã«ã«ããããªã«
4.4ïœãåŸãããã IRïŒ2250cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«âã·
ãªã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢
ã³ããã¹ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ãã
ã«ããããã©ã³â7αâã«ã«ããããªã«ïŒïŒ
ïŒïœãç¡æ°ŽããªãªãŒã«100mlã«æº¶è§£ãããã®
溶液ã«â70âã§ããªãªãŒã«äžã®1.2ã¢ã«ã®æ°Ž
çŽ åã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²13mlãæ·»
å ãããã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æã
ããåŒç¶ãããã®æº¶æ¶²ã飜åã¯ãšã³é žæº¶æ¶²50
mlã§åè§£ããæ°ŽçžããšãŒãã«ã§æœåºããåã
ãææ©çžãæ°Žã§äžåæŽæµããç¡«é žãããªãŠã
äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ãããïŒïŒ
5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãªã«ãªã
ã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹
ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ãâãã«ãã
ããã©ã³â7αâã«ã«ãã¢ã«ããã3.5ïœãåŸ
ãããã IRïŒ1725cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³
ããã¹ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ããã«
ããããã©ã³â7αâã«ã«ãã¢ã«ããã1.1ïœ
ãã¢ã»ãã³50mlã«æº¶è§£ãããã®æº¶æ¶²ã«ïŒâã§
ãžãšãŒã³ãºïŒJonesïŒæº¶æ¶²2.7mlãæ·»å ããã
ã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æãããåŒç¶
ãããã®æº¶æ¶²ãæ°Ž300mlã§çšéãããžã¯ãã«
ã¡ã¿ã³ã§æœåºãããåããææ©çžã1nèæ§
ãœãŒãæ¶²ã§æœåºããæ°Žçžããžã¯ãã«ã¡ã¿ã³ã§
æŽæµããå·ããæ¿ç¡«é žã§é žæ§ã«ãããžã¯ãã«
ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµããç¡«é žãã
ãªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ããã
èç¹260âã262âã®3βâïŒ7αâã«ã«ããã·â
17βâããããã·â15βïŒ16βâã¡ãã¬ã³âïŒ
âãªããœâïŒâã¢ã³ããã¹ãã³â17αâã€
ã«ïŒããããªã³é žã©ã¯ãã³528ïœãåŸãããã UVïŒÎµ238ïŒ16900ã (B) 3βâïŒ7αâã«ã«ããã·â17βâããããã·â
6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªã
ãœâïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒããã
ãªã³é žã©ã¯ãã³ïŒ ïŒ ïŒâïŒ17βâããããã·â15βïŒ16βâã¡ã
ã¬ã³âïŒâãªããœâïŒâã¢ã³ããã¹ãã³â
17αâã€ã«ïŒããããªã³é žã©ã¯ãã³ïŒè£œé
ã¯ã西ãã€ãåœç¹èš±å ¬éå ¬å ±ç¬¬2652761å·ã
åç §ïŒ10ïœãç©è³ªã§ãªãã·å¡©åç19mlãã¯ã
ããã«ã 300mlãé ¢é žãããªãŠã 10ïœåã³ã¡
ãã©ãŒã«300mlã®æžæ¿æ¶²ã«å ããæ²žéš°ãããŸ
ã§å ç±ããããã®æžæ¿æ¶²ã«ïŒæéã§ãªãã·å¡©
åç19mlãæ»Žå ãããããããã«ïŒæéç ®æ²ž
ãããå·åŽåŸã飜åçé žãããªãŠã æº¶æ¶²ãæ»Ž
å ããææ©çžãåé¢ããç空äžã§æ¿çž®ããã
åŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ãã«ã¡
ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠçã
ãããšã«ãã€ãŠç²Ÿè£œãããèç¹170.5âã
172.5âã®ïŒâïŒ17βâããããã·âïŒïŒïŒïŒ
15βïŒ16βâãã¹âã¡ãã¬ã³âïŒâãªããœâ
ïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒâããã
ãšã³é žã©ã¯ãã³7.2ïœãåŸãããã UVïŒÎµ261ïŒ11300ã ïŒ ïŒâïŒ17βâããããã·âïŒïŒïŒïŒ15βïŒ
16βâãã¹âã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒããããªã³é žã©
ã¯ãã³ïŒïœã«ãšã¿ããŒã«250mläžã§ç¡æ°Žé ¢é ž
ãããªãŠã 3.5ïœåã³ïŒïŒ ççŽ äžã®ãã©ãžãŠ
ã 500mgãæ·»å ããããã«æ²žéš°å ç±ããªãã
ïŒæéã§ãšã¿ããŒã«40mläžã®ã·ã¯ããããµã³
1.4mlãå°ããã€æ·»å ãããæ¬¡ã«ããã®æº¶æ¶²
ããè§Šåªãå¥ããæ¶²ãç空äžã§æ¿çž®ã
ããåŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ã
ã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠ
çããããšã«ãã€ãŠç²Ÿè£œãããèç¹228.5â
ã231âã®ïŒâïŒ17βâããããã·âïŒâã¡ã
ã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒïŒ
ïŒâã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒãã
ããªã³é žã©ã¯ãã³5.9ïœãåŸãããã UVïŒÎµ290ïŒ23800ã ïŒ ïŒâïŒ17βâããããã·âïŒâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒïŒïŒ
âã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒããã
ãªã³é žã©ã¯ãã³6.8ïœã«ç¡æ°Žããã©ãããã
ã©ã³150mläžã§ããªãªãŒã«äžã®ã·ã¢ã³åãžãš
ãã«ã¢ã«ãããŠã ã®ïŒã¢ã«ã®æº¶æ¶²35mlãæ·»å
ãããã®æº¶æ¶²ãéæµäžã§ïŒæéç ®æ²žããå·åŽ
ãã1nèæ§ãœãŒãæ¶²100mläžã«å ããããžã¯
ãã«ã¡ã¿ã³ã§ã®æœåºåŸããã®æº¶æ¶²ã20ïŒ ç¡«é ž
ã§æŽæµããæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããã€ç空äžã§æ¿çž®ãããïŒâïŒ7αâ
ã·ã¢ãâ17βâããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒããããªã³é žã©
ã¯ãã³6.7ïœãç²è£œçæç©ãšããŠåŸãããã UVïŒÎµ236ïŒ12200ã ïŒ ïŒâïŒ7αâã·ã¢ãâ17βâããããã·â6α
âã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªã
ãœâïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒãã
ããªã³é žã©ã¯ãã³ïŒç²è£œçæç©ïŒ6.3ïœãç¡
æ°Žããã©ããããã©ã³400mlã«æº¶è§£ãããã®
溶液ãâ70âã«å·åŽããããã®æº¶æ¶²ã«ãã«ãª
ãŒã«äžã®1.2ã¢ã«ã®æ°ŽçŽ åã¢ã«ãããŠã ãžã€
ãœããã«æº¶æ¶²42mlãæ»Žå ãããã®æº¶æ¶²ãâ70
âã§ïŒæéããã«æ¹æããã¯ãšã³é žæº¶æ¶²200
mlã§åè§£ãããžã¯ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§
äžåæŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããã
ã€ç空äžã§æ¿çž®ãããåŸãããç²è£œçæç©ã
çªé žã²ã«ã§ãžã¯ãã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ã
ããã°ã©ãã€ãŒåŠçããããšã«ãã€ãŠç²Ÿè£œã
ãã3βïŒ5â²âãžããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³
âãïŒ17βâ1â²ïŒâã¹ããâ2â²ããã«ããããã©
ã³â7αâã«ã«ããããªã«5.1ïœãåŸãããã IRïŒ3650ã3520ã2260ã1710cm-1ã ïŒ 3βïŒ5â²âãžããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³
ãïŒ17βâ1â²ïŒâã¹ããâ2â²ããã«ããããã©ã³
â7αâã«ã«ããããªã«ïŒïœãç¡æ°Žãžã¡ãã«
ãã«ã ã¢ãã100mlã«æº¶è§£ãããã®æº¶æ¶²ãã€
ãããŸãŒã«ïŒïœåã³ç¬¬äžããã«âãžã¡ãã«ã·
ãªã«ã¯ããªã5.5ïœãšäžç·ã«å®€æž©ã§ïŒæéæ¹
æãããã®æº¶æ¶²ãæ°·æ°Ž1000mläžã«å ããæ²æ®¿
ããæ²æ®¿ç©ãå¥ãããžã¯ãã«ã¡ã¿ã³ã«åŒå
ããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããç空äžã§æ¿
çž®ãããïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ã
ã«ã·ãªã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâ
ã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒ
âã¹ããâ2â²ããã«ããããã©ã³â7αâã«ã«
ããããªã«6.2ïœãæ²¹ãšããŠåŸãããã IRïŒ2260cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒâã¹ã
ãâ2â²ããã«ããããã©ã³â7αâã«ã«ããã
ãªã«6.0ïœãç¡æ°ŽããªãªãŒã«150mlã«æº¶è§£ãã
ãã®æº¶æ¶²ã«â70âã§ãã«ãªãŒã«äžã®1.2ã¢ã«
ã®æ°ŽçŽ åã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²25ml
ãæ·»å ãããã®æº¶æ¶²ãâ70âã§ïŒæéæ¹æ
ããâ20âã§ïŒæéæ¹æãããåŒç¶ãããã®
溶液ã飜åã¯ãšã³é žæº¶æ¶²100mlã§åè§£ããæ°Ž
çžããšãŒãã«ã§æœåºããåããææ©çžãæ°Žã§
äžåæŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããã
ã€ç空äžã§æ¿çž®ãããçªé žã²ã«ã§ãããµã³ïŒ
é ¢é žãšã¹ãã«ã§ã®ã¯ãããã°ã©ãã€ãŒåŠç
åŸãïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·
ãªã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ã
ã¬ã³âïŒâã¢ã³ããã¹ãã³âãïŒ17βâ1â²ïŒâã¹
ããâ2â²ããã«ããããã©ã³â7αâã«ã«ãã¢
ã«ããã4.9ïœãæ²¹ãšããŠåŸãããã IRïŒ1730cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒâã¹ã
ãâ2â²ããã«ããããã©ã³â7αâã«ã«ãã¢ã«
ããã4.5ïœãã¢ã»ãã³125mlã«æº¶è§£ãããã®
溶液ã«ïŒâã§ãžãšãŒã³ãºïŒJonesïŒæº¶æ¶²10ml
ãæ·»å ãããã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æ
ãããåŒç¶ãããã®æº¶æ¶²ãæ°Ž500mlã§çšéãã
ãžã¯ãã«ã¡ã¿ã³ã§æœåºãããåããææ©çžã
1nèæ§ãœãŒãæ¶²ã§æœåºããæ°Žçžããžã¯ãã«
ã¡ã¿ã³ã§æŽæµããå·ããæ¿ç¡«é žã§é žæ§ã«ãã
ãžã¯ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµãã
ç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿
çž®ããã3βâïŒ7αâã«ã«ããã·â17βâãã
ããã·â6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³
âïŒâãªããœâïŒâã¢ã³ããã¹ãã³â17αâ
ã€ã«ïŒããããªã³é žã©ã¯ãã³2.45ïœãåŸãã
ãã UVïŒÎµ239ïŒ14400ã æ¬çºæã«ããååç©ã¯ãå»è¬åã補é ãããã
ã®çè¬è£œå€åŠã®èªäœå ¬ç¥ã®æ¹æ³ã«ããçµå£æäžå
ã³éçµå£çæäžäœ¿çšãããã æ¬¡ã«ãæ¬çºæã«ããååç©ã嫿ããå»è¬åã®
è¬çäœçšã®ç¢ºèªè©Šéšã«ã€ããŠèª¬æããã ïŒ ãŠãµã®ã®å宮现è質ãŸã«äžã®ããã²ã¹ãâã²
ã³åå®¹äœ ãŠãµã®ã®åå®®ãã¢ã²ããŒãã®çްè質ãŸã«ã¯ã
èçœè³ªãå容äœååã嫿ãããã®å容äœåå
ã¯ãé«ãèŠªåæ§åã³äœãèœåãæããããã²ã¹
ããã³ãçµåããããã®å容äœãæšèåãããŠ
ããªãåæã²ã¹ã¿ãŒã²ã³ã®ååšäžã« 3Hâãã
ã²ã¹ããã³ãšäžç·ã«ææž©ä¿æããå Žåã«ã¯ãç¹
城ã®ããæäžéã«äŸåããå€äœæ²ç·ãåŸãã
ãããã®æ§è³ªã¯ãæ°èŠååç©ã®äžè¬çãªèšèŒã«
ãšã€ãŠå¥œé©ãªãã®ã§ããã ç©è³ªïŒ 49CiïŒããªã¢ã«ã®ç¹ç°ç掻éãæããããã²
ã¹ããã³â1αïŒ2αâ 3HïŒïœïŒïŒœã¯ãè±åœã®ã¢
ã¡ã«ã·ã€ã 瀟ïŒAmershamïŒããå ¥æã§ãã
ã»ãã¢ããã¯ã¹ïŒïŒSephadexïŒïŒ§â10ã¯ãã¹ãŠ
ãšãã³åœã®ãã¢ã«ãã·ã¢ç€ŸïŒPharmaciaïŒã
ãå ¥æã§ãããä»ã®å šãŠã®ç©è³ªã¯ãåæã®çšåºŠ
ã«å¿ããŠåæ¥çã«å ¥æã§ããã åç©ïŒ äœé2.5ãïŒKgã®æçãããŠãµã®ããã³ãã¿
ãŒã«ã§éº»é ããŠåµå·£åé€ãããåå®®ãæåºãã
ïŒãïŒæ¥åã«ããã®åç©ã«è¡éº»æ²¹0.2mlã«æº¶è§£
ããããšã¹ãã©ãžãªãŒã«ãã³ãŸãšãŒã10ÎŒïœã
æ¯æ¥ç®äžæ³šå°ããããã®åç©ã麻é ã«ãããã
ã€é éèã«ãã€ãŠçè¡ãããåå®®ãæåºããã
ã€å·ããé£å¡©æ°Žã§æŽæµããã 现è質ãŸã«ã®è£œé å šãŠã®åŸç¶ã®å·¥çšãïŒâã®å·ãã宀ã®äžã§å®
æœãããåå®®ããççæ§èèªçµç¹ãåãé€ãã
ãã®åå®®ãæž©åã«æŽæµããè¡ç®¡ããæ®åãã幟
ããã®è¡æ¶²ãé€å»ããããã®åå®®çµç¹ïŒïœã
EDTA1.5Ã10-3ã¢ã«ïŒåã³ã°ãªã»ããŒã«30
ïŒ ã嫿ãã0.01ã¢ã«ïŒããªã¹ç·©è¡æ¶²ïŒmlã
PH7.5ãäžã«å ¥ãããã€éã¿ã§å°çã«è£æããã
ãã®çµç¹ããŠã«ãã©âã¿ãŒã©ãã¯ã¹ïŒUltraâ
TurraxïŒïŒJanke u.Kunkel瀟ããã€ãåšïŒã
çšããŠå質åãããã€ç·©è¡æ¶²ïŒmlåœãçµç¹ïŒïœ
ã®æçµæ¿åºŠã«ãŸã§ç·©è¡æ¶²ã§æŽæµãããé å¿åé¢
管ã«ç§»ããããã®å質ç©è³ªããœã«ãã«
ïŒSorvallïŒé å¿åé¢åšäžã§1000Ãïœã§10åéé
å¿åé¢ããããŸããäžæŸã¿æ¶²ãããã¯ãã³
ïŒBeckmanïŒé å¿åé¢åšãååŒïŒ¬ ïŒâ50äžã§
105000Ãïœã§90åéé å¿åé¢ãããèèªå±€ã®äž
ã®äžæŸã¿æ¶²ãæéãããã€â18âã§è²¯èµããã ææž©ä¿æ ãã®ã€ã©ã®è©äŸ¡åæã®åã«ãå宮现è質ãŸã«
ãã³ã«ããŸãŒã«ã§åŠçãããã©ã³ã¹ã³ã«ãã³ã®
çµåéšäœã飜åããããã³ã«ããŸãŒã«10ÎŒ
ïŒ10-4ã¢ã«ïŒïŒã现è質ãŸã«0.4mlã«æ·»å ãã
ãã€ïŒâã§15åéä¿æããã 3Hâããã²ã¹ããã³10ÎŒïŒæçµæ¿åºŠ10-7ã¢
ã«ïŒïŒããã³æšæºæ²ç·ã®ããã«æšèåãããŠ
ããªãããã²ã¹ããã³10ÎŒãŸãã¯é©åœãªæ¿åºŠ
ã®è©Šéšç©è³ª10ÎŒã现è質ãŸã«20ÎŒã«æ·»å ã
ããã¹ããã€ãããæçµæ¿åºŠãïŒïŒ ãäžå»»ããª
ããããªçšåºŠã«ãšã¿ããŒã«ã«æº¶è§£ãããåžéã®
ããã®ç·©è¡æ¶²ã¯ãã°ãªã»ããŒã«10ïŒ ã®ã¿ã嫿
ããŠããããã®ã€ã©è©ŠæãïŒâã§60åéææž©ä¿
æãããææž©ä¿æåŸãã°ãªã»ããŒã«10ïŒ ãæã
ãç·©è¡æ¶²0.46mlãæ·»å ãã0.2mlã®ã¢ãªã³ãŒã
ãã«ã©ã äžã«æœããã ã»ãã¢ããã¯ã¹ïŒ§â10ã«ã©ã äžã§ã®åé¢ ã»ãã¢ããã¯ã¹ïŒ§â10ããEDTA1.5Ã10-3
ã¢ã«ïŒåã³ã°ãªã»ããŒã«10ïŒ ã嫿ãã10-2
ã¢ã«ïŒããªã¹ç·©è¡æ¶²ãPH7.5ãäžã«æžæ¿ãã
ããä»ã«ã¯äœãåããŠããªãç³è±ç¶¿æ¯ã®å°ããª
æ ãæãã容ç©çŽïŒmlã®ãã¹ããŒã«åŸ®é管ãã«
ã©ã ãšããŠäœ¿çšãããå ã®è©Šéšã«ãããããã²
ã¹ããã³ãçµåããå容äœã¯ç·©è¡æ¶²ïŒmlã§æº¶é¢
ãããããšã倿ãããçµåããŠããªãããã²
ã¹ããã³ãç·©è¡æ¶²ãšã¡ã¿ããŒã«ãšã®æ··åç©ïŒml
ïŒïŒïŒïŒãïœïŒïœïŒãçšããŠã«ã©ã ããå®éç
ã«æŸåºããã æº¶åºæ¶²ã®å®¹éãç·©è¡æ¶²ïŒã¡ã¿ããŒã«ã§èª¿ç¯ã
ãåŸãæŸå°èœãæ¶²äœã·ã³ãã¬ãŒã·ãšã³èšæ°åšäž
ã§ã€ã³ã¹ã¿ã²ã«ïŒInstagelïŒäžã®åæ¹ã®ç»å
ã®å Žåã«ã€ããŠèšæ°ããã ä»ã®ããã²ã¹ããŒã²ã³ã®çžå¯ŸççµåèŠªåæ§ã
枬å®ããããã«ã 3Hâããã²ã¹ããã³ãšã
æšèåãããŠããªãç©è³ªãšã®å€äœã察æ°ã¢ã«æ¿
床ã«å¯ŸããçŸåçã§ã®çµåãšããŠããããã
ãããã®ãããªå€äœæ²ç·ã¯ãããžãã察æ°å€æ
ã«ãã€ãŠç·ç¶åããããšãã§ãããååç©ã®æŽ»
æ§ã¯ãããã²ã¹ããã³ãšç䟡ã®å€äœãåŸããã
ã®æ¿åºŠã®åæ°ãšèŠå®ãããŠããç«¶åçãã¢ã¯ã¿
ãŒãšããŠç€ºãããã ïŒ ã©ããåç«è ºã®çްè質ãŸã«äžã®ç·æ§ãã«ã¢ã³
åå®¹äœ ã©ããåç«è ºã®ãã¢ã²ããŒãã®çްè質ãŸã«
ã¯ãèçœè³ªãå容äœååã嫿ãããã®å容äœ
ååã¯ãé«ãèŠªåæ§åã³äœãèœåãæãããžã
ãããã¹ãã¹ããã³ïŒDHTïŒãçµåãããã
ã®å容äœãæšèåãããŠããªãåæç·æ§ãã«ã¢
ã³ã®ååšäžã« 3Hâãžããããã¹ãã¹ããã³ãš
äžç·ã«ææž©ä¿æããå Žåã«ã¯ãç¹åŸŽã®ããæäž
éã«äŸåããå€äœæ²ç·ãåŸãããããã®æ§è³ª
ã¯ãæ°èŠååç©ã®äžè¬çãªèšèŒã«ãšã€ãŠå¥œé©ãª
ãã®ã§ããã ç©è³ªïŒ 60CiïŒããªã¢ã«ã®ç¹ç°ç掻éãæãã5αâ
ãžãããâ1αïŒ2αâ 3HïŒïœïŒïŒœâãã¹ãã¹ãã
ã³ã¯ãè±åœã®ã¢ã¡ã«ã·ã€ã 瀟ïŒAmershamïŒ
ããå ¥æã§ããã»ãã¢ããã¯ã¹ïŒïŒSephadexïŒ
â10ã¯ãã¹ãŠãšãã³åœã®ãã¢ã«ãã·ã¢ç€Ÿ
ïŒPharmaciaïŒããå ¥æã§ãããä»ã®å šãŠã®ç©
質ã¯ãåæã®çšåºŠã«å¿ããŠåæ¥çã«å ¥æã§ã
ãã åç©ïŒ äœé300ã400ïœã®æçããã©ããïŒç³»çµ±ïŒ
Wistarã墿®ïŒSchering瀟ïŒããšãŒãã«ã§éº»
é ããŠåµå·£åé€ãããåµå·£ãåé€ããŠãã20ã
24æéåŸã«ããã®åç©ãæé ããã€çè¡ããã
è ºãæ°·å·åŽããã¹ã¯ããŒã¹0.25mlïŒäžã«æé
ããã 现è質ãŸã«ã®è£œé å šãŠã®åŸç¶ã®å·¥çšãïŒâã®å·ãã宀ã®äžã§å®
æœãããåç«è ºããççæ§èèªçµç¹ãåãé€
ãããã€å§æŸããè¡ç®¡ããæ®åãã幟ããã®è¡
æ¶²ãé€å»ããããã®åç«è ºçµç¹ã濟çŽäžã§ãã
ãããããã€éã¿ã§å°çã«è£æããããã®åç«
è ºçµç¹ïŒïœã0.01ã¢ã«ïŒããªã¹ç·©è¡æ¶²0.6mlã
PH7.5ãäžã«å ¥ãããã€ã¢ãªã³ãŒããããã¿ãŒ
âãšã«ãã ïŒPotterâElvehjemïŒïŒmlãšäžç·
ã«å質åããã詊æãæéãããã€ç·©è¡æ¶²ïŒml
åœãçµç¹ïŒïœã®æçµæ¿åºŠã«ãŸã§ç·©è¡æ¶²ã§åžéã
ãããã®ãã¢ã²ããŒããããã¯ãã³
ïŒBeckmanïŒé å¿åé¢åšãååŒïŒ¬ ïŒâ50äžã§
105000Ãïœã§90åéé å¿åé¢ãããèèªå±€ã®äž
ã®äžæŸã¿æ¶²ãæéãããã€â18âã§ã¢ãªã³ãŒã
ã§è²¯èµããã ææž©ä¿æ 3HâDHT10ÎŒïŒæçµæ¿åºŠïŒÃ10-8ã¢ã«ïŒ
ïŒããã³æšæºæ²ç·ã®ããã«æšèåãããŠããª
ãDHT10ÎŒãŸãã¯é©åœãªæ¿åºŠã®è©Šéšç©è³ª10ÎŒ
ã现è質ãŸã«40ÎŒã«æ·»å ãããã¹ããã€ã
ããæçµæ¿åºŠãïŒïŒ ãäžå»»ããªããããªçšåºŠã«
ãšã¿ããŒã«ã«æº¶è§£ããããã®ã€ã©è©ŠæãïŒâã§
120åéææž©ä¿æãããææž©ä¿æåŸãç·©è¡æ¶²
0.44mlãæ·»å ãã0.2mlã®ã¢ãªã³ãŒããã«ã©ã
äžã«æœããã ã»ãã¢ããã¯ã¹ïŒ§â10ã«ã©ã äžã§ã®åé¢ ã»ãã¢ããã¯ã¹ïŒ§â10ããããªã¹ç·©è¡æ¶²0.01
ã¢ã«ïŒã¢ã«ãPH7.5ãäžã«æžæ¿ããããä»ã«
ã¯äœãåããŠããªãç³è±ç¶¿æ¯ã®å°ããªæ ãæã
ã容ç©çŽïŒmlã®ãã¹ããŒã«åŸ®é管ãã«ã©ã ãšã
ãŠäœ¿çšãããå ã®è©Šéšã«ãããDHTãçµåã
ãå容äœã¯ç·©è¡æ¶²ïŒmlã§æº¶é¢ãããããšã倿
ãããçµåããŠããªãDHTãç·©è¡æ¶²ãšã¡ã¿ã
ãŒã«ãšã®æ··åç©ïŒmlïŒïŒïŒïŒãïœïŒïœïŒãçšã
ãŠã«ã©ã ããå®éçã«æŸåºããã æº¶åºæ¶²ã®å®¹éãç·©è¡æ¶²ïŒã¡ã¿ããŒã«ã§èª¿ç¯ã
ãåŸãæŸå°èœãæ¶²äœã·ã³ãã¬ãŒã·ãšã³èšæ°åšäž
ã§ã€ã³ã¹ã¿ã²ã«ïŒInstagelïŒäžã®åæ¹ã®ç»å
ã®å Žåã«ã€ããŠèšæ°ããã ä»ã®æŸå°èœã¹ããã€ãã®çžå¯ŸççµåèŠªåæ§ã
枬å®ããããã«ãæšèåãããŠããªãç©è³ªã«ã
ã 3HâDHTã®å€äœã察æ°ã¢ã«æ¿åºŠã«å¯Ÿã
ãçŸåçã§ã®çµåãšããŠããããããããã®ã
ããªå€äœæ²ç·ã¯ããããããŒãïŒRodbardïŒä»
ã«ããããžããïŒå¯Ÿæ°å€æã«ãã€ãŠç·ç¶åãã
ããšãã§ããïŒJ.Lab.Clin.Med.74ïŒ770ã
1969ïŒãç«¶åçãã¢ã¯ã¿ãŒïŒKFïŒã¯ã詊éšè©Šæ
ã®æ¿åºŠãšãåºæºç©è³ªïŒããªãã¡ãDHTïŒã®æ¿
床ãšã®å²åãšããŠèŠå®ãããã ä»ã®ç·æ§ãã«ã¢ã³ã®çžå¯ŸççµåèŠªåæ§ãæž¬å®
ããããã«ã 3Hâãžããããã¹ãã¹ããã³
ãšãæšèåãããŠããªãç©è³ªãšã®å€äœã察æ°ã¢
ã«æ¿åºŠã«å¯ŸããçŸåçã§ã®çµåãšããŠãããã
ããããã®ãããªå€äœæ²ç·ã¯ãããžãã察æ°å€
æã«ãã€ãŠç·ç¶åããããšãã§ãããååç©ã®
掻æ§ã¯ããžããããã¹ãã¹ããã³ãšç䟡ã®å€äœ
ãåŸãããã®æ¿åºŠã®åæ°ãšèŠå®ãããŠããç«¶å
çãã¢ã¯ã¿ãŒãšããŠç€ºãããã
åéã®çµåã¯ã飜åãããŠãããåã¯äºéçµåã§
ãããã§ç€ºããã7αâã¢ã«ã³ãã·ã«ã«ããã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³åå
ç©ã®è£œé æ³ã«é¢ãããã®æ¹æ³ã¯ãèªäœå ¬ç¥ã®æ¹æ³
ã§ãäžè¬åŒïŒïŒïŒ ãåŒäžãR1ã¯åèšã®ãã®ã衚ãããã§ç€ºããã
ååç©ãåå¿ãããŠäœçŽã¢ã«ãã«âãšã¹ãã«ã«å€
ããå Žåã«ãã€ãŠã¯â³1âäºéçµåãå°å ¥ãå
ã³ïŒåã¯ã©ã¯ãã³ç°ãçžåœããããããªã³é žâã«
ãªãŠã å¡©ã«éç°ããããšãç¹åŸŽãšããã åŒïŒïŒã®7αâã«ã«ããã·ã«ååç©ã®ãšã¹ã
ã«åã¯ãèªäœå ¬ç¥ã®æ¹æ³ã«ãããã«ã«ãã³é žãšã
ãžã¢ãŸã¢ã«ã«ã³ãäŸãã°ãžã¢ãŸã¡ã¿ã³åã¯ãžã¢ãŸ
ãšã¿ã³ãšããé©åœãªæº¶å€äžãäŸãã°ãžãšãã«ãšãŒ
ãã«ãããã©ããããã©ã³ãããã¯ãžãªããµã³å
ã¯ãããæº¶å€ã®æ··åç©äžã§ïŒâã25âãæå©ã«ïŒ
âãïŒâã®æž©åºŠã§åå¿ãããåŒç¶ãéå°ã®ãžã¢ãŸ
ã¢ã«ã«ã³ãææ©é žãäŸãã°æ°·é ¢é žåã¯é ç³é žãæ·»
å ããããšã«ãã€ãŠåè§£ãããã€ãã®æº¶æ¶²ããç
空äžã§æº¶å€ãé€å»ããããšã«ããè¡ãªããããã
ã®ãšã¹ãã«åã¯ãåœæ¥è ã«å ¬ç¥ã®æ¹æ³ã«ããåŒ
ïŒïŒã®ã«ã«ãã³é žãšãäŸãã°ã¯ãã«è»é žããã«
âåã¯ã€ãœããã«âãšã¹ãã«ã®ãããªã¯ãã«è»é ž
âã¢ã«ãã«ãšã¹ãã«ãšããé©åœãªæº¶å€äžãäŸãã°
ããã©ããããã©ã³åã¯ãžãªããµã³äžã§HClâå
容察ãšããŠã®äŸãã°ããªãšãã«ã¢ãã³ã®ãããªïŒ
çŽã¢ãã³ã®ååšäžã§ïŒâã20âãæå©ã«ïŒâãïŒ
âã®æž©åºŠã§åå¿ãããäžè¬åŒïŒïŒïŒ ãåŒäžãR1ãåã³ïŒ¹ã¯ããããåèšã®ãã®ã
衚ãããã§ç€ºãããæ··åç¡æ°Žç©ã«å€ããããšã«ã
ãã宿œããããšãã§ããã åŸåŠçããããã«ã¯ãïŒçŽã¢ãã³âå¡©é žå¡©ã®åœ¢
æãããæ²æ®¿ç©ãå¥ããæ¶²ããæº¶å€ãé€å»
ãããã®éã«åŒïŒïŒã®æ··åç¡æ°Žç©ã¯ç²è£œçæç©
ãšããŠåŸãããã äžè¬åŒïŒïŒã®ææã®ãšã¹ãã«ãåŸãããã«
ã¯ãåŒïŒïŒã®ååç©ãã¢ã«ã³ãŒã«R2âOHïŒäœ
ããR2ã¯åèšã®ãã®ã衚ããïŒã«æº¶è§£ãããã®
溶液ã24ã72æéãæå©ã«48æé沞隰å ç±ããã
ã®åŸã«æº¶å€ãçå»ããåŒïŒïŒã®ååç©ãåé¢ã
ãã â³1âäºéçµåã®å°å ¥ã¯ãèªäœå ¬ç¥ã®æ¹æ³ã«ã
ãè¡ãªãããååŠçåã¯åŸ®çç©åŠçæ¹æ³ã§è¡ãªã
ããšãã§ãããïŒïŒïŒâè±æ°ŽçŽ åã«é©ããååŠç
è±æ°ŽçŽ åå€ã¯ãäŸãã°äºé žåã»ã¬ã³ãïŒïŒïŒâãž
ã¯ãã«âïŒïŒïŒâãžã·ã¢ããã³ãŸããã³ãã¯ãã©
ãã«ãäžé ¢é žã¿ãªãŠã åã¯åé ¢é žéã§ããã ïŒïŒïŒâè±æ°ŽçŽ åã«é©ãã埮çç©ã¯ãäŸãã°å
è£èãæ®ã«äŸãã°åäžATCC6946ã®ãããªã¢ã«ã¹
ããã¯ã¿ãŒå±ïŒArthrobacterïŒã®ãã®ïŒäŸãã°
ããã«ã¹ã»ã¬ã³ãã¹ïŒB.lentusïŒATCC13805å
ã³ããã«ã¹ã»ã¹ããšãªã¯ã¹ïŒB.sphaericusïŒ
ATCC7055ã®ãããªããã«ã¹å±ïŒBacillusïŒã®ã
ã®ïŒäŸãã°ç·è¿èïŒP.aeruginosaïŒIFO3505ã®ã
ããªã·ãŠãŒãã¢ãã¹å±ïŒPseudmonasïŒã®ãã®ïŒ
äŸãã°ãã©ããã¯ããªãŠã ã»ãã©ããã»ã³ã¹ïŒF.
flavescensïŒIFO3058ã®ãããªãã©ããã¯ããªãŠ
ã å±ïŒFlavobacteriumïŒã®ãã®ïŒäŸãã°ã©ã¯ã
ããã«ã¹ã»ãã¬ãã¹ïŒL.brevisïŒIFO3345ã®ãã
ãªã©ã¯ãããã«ã¹å±ïŒLactobacillusïŒãªãã³ã«
äŸãã°ãã«ã«ãžã¢ã»ãªãã«ïŒN.opacaïŒ
ATCC4276ã®ãããªãã«ã«ãžã¢å±ïŒNocardiaïŒ
ã®ãã®ã§ããã ïŒïŒïŒâè±æ°ŽçŽ åã¯ãååŠçã«å®æœããã®ã奜
ãŸããããã®ããã«ã¯ãïŒïŒïŒâãžãããã¹ãã
ã€ããé©åœãªæº¶å€äžã§è±æ°ŽçŽ åå€ãšäžç·ã«é·æé
å ç±ãããé©åœãªæº¶å€ã¯ãäŸãã°ãžãªããµã³ã第
äžãã¿ããŒã«ãããã©ããããã©ã³ããã«ãªãŒ
ã«ããã³ãŸãŒã«ãªããã¯ãããæº¶å€ã®æ··åç©ã§ã
ãã åå¿ã¯ãæ°æéåŸã«çµçµãããåå¿ã¯èå±€ã¯ã
ããã°ã©ãã€ãŒã«ãã€ãŠè¡ãªãã®ãæãŸãããå
å¿æ··åç©ã¯ãåºçºç©è³ªãåå¿ããŠããå Žåã«åŸåŠ
çãããã ã©ã¯ãã³ç°ã®å Žåã«ãã€ãŠã¯åŒç¶ãéç°ã¯ãå
æ§ã«èªäœå ¬ç¥ã®æ¹æ³ã«ããè¡ãªãããããã®ãã
ã«ã¯ãã©ã¯ãã³ãåžèæ§ã«ãªæ¶²ãšäžç·ã«å ç±ãã
ãã®éã«ïŒâ眮æããããªã³é žã®ã«ãªãŠã å¡©ã¯åœ¢
æãããã åå¿ã®çµçµåŸããã®åå¿æ··åç©ã¯ãåžžæ³ã§ãäŸ
ãã°æ²æ®¿ç©ãæœåºç©ãåçµæ¶æ³åã³ïŒåã¯ã«ã©ã
ã¯ãããã°ã©ãã€ãŒæ³ã«ãã€ãŠåŸåŠçãããã éå§å€çµæç©ã®è£œé (A) ïŒâïŒ7αâã«ã«ããã·â17βâããããã·â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢ã³
ããã¹ãã³â17αâã€ã«ïŒâããããªã³é žã©ã¯
ãã³ïŒ ïŒ ïŒâïŒ17βâããããã·â15βïŒ16βâã¡ã
ã¬ã³âïŒâãªããœâïŒïŒïŒâã¢ã³ããã¹ã¿â
ãžãšã³â17αâã€ã«ïŒâããããªã³é žã©ã¯ã
ã³ïŒè£œé ã¯è¥¿ãã€ãåœç¹èš±å ¬éå ¬å ±ç¬¬
2652761å·ãåç §ïŒ5.3ïœãç¡æ°Žããã©ããã
ãã©ã³100mlã«æº¶è§£ãããã®æº¶æ¶²ã«ã¢ã«ãŽã³
é°å²æ°äžã§ãã«ãªãŒã«äžã®ã·ã¢ã³åãžãšãã«
ã¢ã«ãããŠã ã®ïŒã¢ã«ã®æº¶æ¶²ã30mlãæ·»å
ãããã®æº¶æ¶²ãéæµäžã§30åéç ®æ²žããå·åŽ
ãã1nèæ§ãœãŒãæ¶²100mläžã«å ããããžã¯
ãã«ã¡ã¿ã³ã§ã®æœåºåŸããã®æº¶æ¶²ã20ïŒ ç¡«é ž
ã§æŽæµããæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããã€ç空äžã§æ¿çž®ãããç²è£œçæç©
ãçªçŽ ã²ã«ã§ãããµã³ïŒã¢ã»ãã³ã§ã¯ããã
ã°ã©ãã€ãŒåŠçããããšã«ãã€ãŠãèç¹238
âã241âïŒâïŒ7αâã·ã¢ãâ17βâãããã
ã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒ
âã¢ã³ããã¹ãã³â17αâã€ã«ïŒâããããª
ã³é žã©ã¯ãã³ïŒïœãåŸãããã αDïŒ68°ãUVïŒÎµ235ïŒ14400ã IRïŒ2250ã1770ã1680ã1640cm-1ã ïŒ ïŒâïŒ7αâã·ã¢ãâ17βâããããã·â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒâããããªã³é ž
ã©ã¯ãã³5.0ïœãç¡æ°Žããã©ããããã©ã³300
mlã«æº¶è§£ãããã®æº¶æ¶²ãâ70âã«å·åŽããã
ãã®æº¶æ¶²ã«ãã«ãªãŒã«äžã®1.2ã¢ã«ã®æ°ŽçŽ å
ã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²35mlãæ»Žå
ãããã®æº¶æ¶²ãâ70âã§ïŒæéããã«æ¹æ
ãã飜åã¯ãšã³é žæº¶æ¶²200mlã§åè§£ãããžã¯
ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµããç¡«é ž
ãããªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ã
ããåŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ã
ã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠ
çããããšã«ãã€ãŠç²Ÿè£œãããèç¹226âã
228âã®3βïŒ5â²âãžããããã·â15βïŒ16βâ
ã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³âã17ïŒÎ²â
1â²ãã¹ããâ2â²ãâãã«ããããã©ã³â7αâ
ã«ã«ããããªã«3.9ïœãåŸãããã IRïŒ3650ã3500ã2250ã1710cm-1ã ïŒ 3βïŒ5â²âãžããããã·â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³âã17ïŒÎ²â1â²ïŒã¹ã
ãâ2â²ãâãã«ããããã©ã³â7αâã«ã«ãã
ããªã«3.65ïœããžã¡ãã«ãã«ã ã¢ãã75mlã«
溶解ãããã®æº¶æ¶²ãã€ãããŸãŒã«2.25ïœåã³
第äžããã«âãžã¡ãã«ã·ãªã«ã¯ããªã4.05ïœ
ãšäžç·ã«å®€æž©ã§ïŒæéæ¹æããæ°·æ°ŽïŒäžã«
å ããæ²æ®¿ããæ²æ®¿ç©ãå¥ãããžã¯ãã«ã¡
ã¿ã³ã«åŒåããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãã
ãã€ç空äžã§æ¿çž®ãããåŸãããç²è£œçæç©
ãçªé žã²ã«ã§ãããµã³ïŒé ¢é žãšã¹ãã«ã§ç²Ÿè£œ
ãããïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«
âã·ãªã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒ
âã¢ã³ããã¹ãã³âãïŒ17βâ1â²ïŒâã¹ããâ
2â²ããã«ããããã©ã³â7αâã«ã«ããããªã«
4.4ïœãåŸãããã IRïŒ2250cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«âã·
ãªã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢
ã³ããã¹ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ãã
ã«ããããã©ã³â7αâã«ã«ããããªã«ïŒïŒ
ïŒïœãç¡æ°ŽããªãªãŒã«100mlã«æº¶è§£ãããã®
溶液ã«â70âã§ããªãªãŒã«äžã®1.2ã¢ã«ã®æ°Ž
çŽ åã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²13mlãæ·»
å ãããã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æã
ããåŒç¶ãããã®æº¶æ¶²ã飜åã¯ãšã³é žæº¶æ¶²50
mlã§åè§£ããæ°ŽçžããšãŒãã«ã§æœåºããåã
ãææ©çžãæ°Žã§äžåæŽæµããç¡«é žãããªãŠã
äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ãããïŒïŒ
5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãªã«ãªã
ã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹
ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ãâãã«ãã
ããã©ã³â7αâã«ã«ãã¢ã«ããã3.5ïœãåŸ
ãããã IRïŒ1725cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³
ããã¹ãã³ãïŒ17βïŒâ1â²ïŒâã¹ããâ2â²ããã«
ããããã©ã³â7αâã«ã«ãã¢ã«ããã1.1ïœ
ãã¢ã»ãã³50mlã«æº¶è§£ãããã®æº¶æ¶²ã«ïŒâã§
ãžãšãŒã³ãºïŒJonesïŒæº¶æ¶²2.7mlãæ·»å ããã
ã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æãããåŒç¶
ãããã®æº¶æ¶²ãæ°Ž300mlã§çšéãããžã¯ãã«
ã¡ã¿ã³ã§æœåºãããåããææ©çžã1nèæ§
ãœãŒãæ¶²ã§æœåºããæ°Žçžããžã¯ãã«ã¡ã¿ã³ã§
æŽæµããå·ããæ¿ç¡«é žã§é žæ§ã«ãããžã¯ãã«
ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµããç¡«é žãã
ãªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿çž®ããã
èç¹260âã262âã®3βâïŒ7αâã«ã«ããã·â
17βâããããã·â15βïŒ16βâã¡ãã¬ã³âïŒ
âãªããœâïŒâã¢ã³ããã¹ãã³â17αâã€
ã«ïŒããããªã³é žã©ã¯ãã³528ïœãåŸãããã UVïŒÎµ238ïŒ16900ã (B) 3βâïŒ7αâã«ã«ããã·â17βâããããã·â
6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªã
ãœâïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒããã
ãªã³é žã©ã¯ãã³ïŒ ïŒ ïŒâïŒ17βâããããã·â15βïŒ16βâã¡ã
ã¬ã³âïŒâãªããœâïŒâã¢ã³ããã¹ãã³â
17αâã€ã«ïŒããããªã³é žã©ã¯ãã³ïŒè£œé
ã¯ã西ãã€ãåœç¹èš±å ¬éå ¬å ±ç¬¬2652761å·ã
åç §ïŒ10ïœãç©è³ªã§ãªãã·å¡©åç19mlãã¯ã
ããã«ã 300mlãé ¢é žãããªãŠã 10ïœåã³ã¡
ãã©ãŒã«300mlã®æžæ¿æ¶²ã«å ããæ²žéš°ãããŸ
ã§å ç±ããããã®æžæ¿æ¶²ã«ïŒæéã§ãªãã·å¡©
åç19mlãæ»Žå ãããããããã«ïŒæéç ®æ²ž
ãããå·åŽåŸã飜åçé žãããªãŠã æº¶æ¶²ãæ»Ž
å ããææ©çžãåé¢ããç空äžã§æ¿çž®ããã
åŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ãã«ã¡
ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠçã
ãããšã«ãã€ãŠç²Ÿè£œãããèç¹170.5âã
172.5âã®ïŒâïŒ17βâããããã·âïŒïŒïŒïŒ
15βïŒ16βâãã¹âã¡ãã¬ã³âïŒâãªããœâ
ïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒâããã
ãšã³é žã©ã¯ãã³7.2ïœãåŸãããã UVïŒÎµ261ïŒ11300ã ïŒ ïŒâïŒ17βâããããã·âïŒïŒïŒïŒ15βïŒ
16βâãã¹âã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒããããªã³é žã©
ã¯ãã³ïŒïœã«ãšã¿ããŒã«250mläžã§ç¡æ°Žé ¢é ž
ãããªãŠã 3.5ïœåã³ïŒïŒ ççŽ äžã®ãã©ãžãŠ
ã 500mgãæ·»å ããããã«æ²žéš°å ç±ããªãã
ïŒæéã§ãšã¿ããŒã«40mläžã®ã·ã¯ããããµã³
1.4mlãå°ããã€æ·»å ãããæ¬¡ã«ããã®æº¶æ¶²
ããè§Šåªãå¥ããæ¶²ãç空äžã§æ¿çž®ã
ããåŸãããç²è£œçæç©ãçªé žã²ã«ã§ãžã¯ã
ã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ãããã°ã©ãã€ãŒåŠ
çããããšã«ãã€ãŠç²Ÿè£œãããèç¹228.5â
ã231âã®ïŒâïŒ17βâããããã·âïŒâã¡ã
ã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒïŒ
ïŒâã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒãã
ããªã³é žã©ã¯ãã³5.9ïœãåŸãããã UVïŒÎµ290ïŒ23800ã ïŒ ïŒâïŒ17βâããããã·âïŒâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒïŒïŒ
âã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒããã
ãªã³é žã©ã¯ãã³6.8ïœã«ç¡æ°Žããã©ãããã
ã©ã³150mläžã§ããªãªãŒã«äžã®ã·ã¢ã³åãžãš
ãã«ã¢ã«ãããŠã ã®ïŒã¢ã«ã®æº¶æ¶²35mlãæ·»å
ãããã®æº¶æ¶²ãéæµäžã§ïŒæéç ®æ²žããå·åŽ
ãã1nèæ§ãœãŒãæ¶²100mläžã«å ããããžã¯
ãã«ã¡ã¿ã³ã§ã®æœåºåŸããã®æº¶æ¶²ã20ïŒ ç¡«é ž
ã§æŽæµããæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããã€ç空äžã§æ¿çž®ãããïŒâïŒ7αâ
ã·ã¢ãâ17βâããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒâã¢
ã³ããã¹ãã³â17αâã€ã«ïŒããããªã³é žã©
ã¯ãã³6.7ïœãç²è£œçæç©ãšããŠåŸãããã UVïŒÎµ236ïŒ12200ã ïŒ ïŒâïŒ7αâã·ã¢ãâ17βâããããã·â6α
âã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒâãªã
ãœâïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒãã
ããªã³é žã©ã¯ãã³ïŒç²è£œçæç©ïŒ6.3ïœãç¡
æ°Žããã©ããããã©ã³400mlã«æº¶è§£ãããã®
溶液ãâ70âã«å·åŽããããã®æº¶æ¶²ã«ãã«ãª
ãŒã«äžã®1.2ã¢ã«ã®æ°ŽçŽ åã¢ã«ãããŠã ãžã€
ãœããã«æº¶æ¶²42mlãæ»Žå ãããã®æº¶æ¶²ãâ70
âã§ïŒæéããã«æ¹æããã¯ãšã³é žæº¶æ¶²200
mlã§åè§£ãããžã¯ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§
äžåæŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããã
ã€ç空äžã§æ¿çž®ãããåŸãããç²è£œçæç©ã
çªé žã²ã«ã§ãžã¯ãã«ã¡ã¿ã³ïŒã¢ã»ãã³ã§ã¯ã
ããã°ã©ãã€ãŒåŠçããããšã«ãã€ãŠç²Ÿè£œã
ãã3βïŒ5â²âãžããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³
âãïŒ17βâ1â²ïŒâã¹ããâ2â²ããã«ããããã©
ã³â7αâã«ã«ããããªã«5.1ïœãåŸãããã IRïŒ3650ã3520ã2260ã1710cm-1ã ïŒ 3βïŒ5â²âãžããããã·â6αâã¡ãã«â
15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³
ãïŒ17βâ1â²ïŒâã¹ããâ2â²ããã«ããããã©ã³
â7αâã«ã«ããããªã«ïŒïœãç¡æ°Žãžã¡ãã«
ãã«ã ã¢ãã100mlã«æº¶è§£ãããã®æº¶æ¶²ãã€
ãããŸãŒã«ïŒïœåã³ç¬¬äžããã«âãžã¡ãã«ã·
ãªã«ã¯ããªã5.5ïœãšäžç·ã«å®€æž©ã§ïŒæéæ¹
æãããã®æº¶æ¶²ãæ°·æ°Ž1000mläžã«å ããæ²æ®¿
ããæ²æ®¿ç©ãå¥ãããžã¯ãã«ã¡ã¿ã³ã«åŒå
ããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããç空äžã§æ¿
çž®ãããïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ã
ã«ã·ãªã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâ
ã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒ
âã¹ããâ2â²ããã«ããããã©ã³â7αâã«ã«
ããããªã«6.2ïœãæ²¹ãšããŠåŸãããã IRïŒ2260cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒâã¹ã
ãâ2â²ããã«ããããã©ã³â7αâã«ã«ããã
ãªã«6.0ïœãç¡æ°ŽããªãªãŒã«150mlã«æº¶è§£ãã
ãã®æº¶æ¶²ã«â70âã§ãã«ãªãŒã«äžã®1.2ã¢ã«
ã®æ°ŽçŽ åã¢ã«ãããŠã ãžã€ãœããã«æº¶æ¶²25ml
ãæ·»å ãããã®æº¶æ¶²ãâ70âã§ïŒæéæ¹æ
ããâ20âã§ïŒæéæ¹æãããåŒç¶ãããã®
溶液ã飜åã¯ãšã³é žæº¶æ¶²100mlã§åè§£ããæ°Ž
çžããšãŒãã«ã§æœåºããåããææ©çžãæ°Žã§
äžåæŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããã
ã€ç空äžã§æ¿çž®ãããçªé žã²ã«ã§ãããµã³ïŒ
é ¢é žãšã¹ãã«ã§ã®ã¯ãããã°ã©ãã€ãŒåŠç
åŸãïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·
ãªã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ã
ã¬ã³âïŒâã¢ã³ããã¹ãã³âãïŒ17βâ1â²ïŒâã¹
ããâ2â²ããã«ããããã©ã³â7αâã«ã«ãã¢
ã«ããã4.9ïœãæ²¹ãšããŠåŸãããã IRïŒ1730cm-1ã ïŒ ïŒïŒ5â²âãã¹ïŒç¬¬äžããã«âãžã¡ãã«ã·ãª
ã«ãªãã·ïŒâ6αâã¡ãã«â15βïŒ16βâã¡ãã¬
ã³âïŒâã¢ã³ããã¹ãã³ãïŒ17βâ1â²ïŒâã¹ã
ãâ2â²ããã«ããããã©ã³â7αâã«ã«ãã¢ã«
ããã4.5ïœãã¢ã»ãã³125mlã«æº¶è§£ãããã®
溶液ã«ïŒâã§ãžãšãŒã³ãºïŒJonesïŒæº¶æ¶²10ml
ãæ·»å ãããã®æº¶æ¶²ããã®æž©åºŠã§ïŒæéæ¹æ
ãããåŒç¶ãããã®æº¶æ¶²ãæ°Ž500mlã§çšéãã
ãžã¯ãã«ã¡ã¿ã³ã§æœåºãããåããææ©çžã
1nèæ§ãœãŒãæ¶²ã§æœåºããæ°Žçžããžã¯ãã«
ã¡ã¿ã³ã§æŽæµããå·ããæ¿ç¡«é žã§é žæ§ã«ãã
ãžã¯ãã«ã¡ã¿ã³ã§æœåºããæ°Žã§äžåæŽæµãã
ç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãããã€ç空äžã§æ¿
çž®ããã3βâïŒ7αâã«ã«ããã·â17βâãã
ããã·â6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³
âïŒâãªããœâïŒâã¢ã³ããã¹ãã³â17αâ
ã€ã«ïŒããããªã³é žã©ã¯ãã³2.45ïœãåŸãã
ãã UVïŒÎµ239ïŒ14400ã æ¬çºæã«ããååç©ã¯ãå»è¬åã補é ãããã
ã®çè¬è£œå€åŠã®èªäœå ¬ç¥ã®æ¹æ³ã«ããçµå£æäžå
ã³éçµå£çæäžäœ¿çšãããã æ¬¡ã«ãæ¬çºæã«ããååç©ã嫿ããå»è¬åã®
è¬çäœçšã®ç¢ºèªè©Šéšã«ã€ããŠèª¬æããã ïŒ ãŠãµã®ã®å宮现è質ãŸã«äžã®ããã²ã¹ãâã²
ã³åå®¹äœ ãŠãµã®ã®åå®®ãã¢ã²ããŒãã®çްè質ãŸã«ã¯ã
èçœè³ªãå容äœååã嫿ãããã®å容äœåå
ã¯ãé«ãèŠªåæ§åã³äœãèœåãæããããã²ã¹
ããã³ãçµåããããã®å容äœãæšèåãããŠ
ããªãåæã²ã¹ã¿ãŒã²ã³ã®ååšäžã« 3Hâãã
ã²ã¹ããã³ãšäžç·ã«ææž©ä¿æããå Žåã«ã¯ãç¹
城ã®ããæäžéã«äŸåããå€äœæ²ç·ãåŸãã
ãããã®æ§è³ªã¯ãæ°èŠååç©ã®äžè¬çãªèšèŒã«
ãšã€ãŠå¥œé©ãªãã®ã§ããã ç©è³ªïŒ 49CiïŒããªã¢ã«ã®ç¹ç°ç掻éãæããããã²
ã¹ããã³â1αïŒ2αâ 3HïŒïœïŒïŒœã¯ãè±åœã®ã¢
ã¡ã«ã·ã€ã 瀟ïŒAmershamïŒããå ¥æã§ãã
ã»ãã¢ããã¯ã¹ïŒïŒSephadexïŒïŒ§â10ã¯ãã¹ãŠ
ãšãã³åœã®ãã¢ã«ãã·ã¢ç€ŸïŒPharmaciaïŒã
ãå ¥æã§ãããä»ã®å šãŠã®ç©è³ªã¯ãåæã®çšåºŠ
ã«å¿ããŠåæ¥çã«å ¥æã§ããã åç©ïŒ äœé2.5ãïŒKgã®æçãããŠãµã®ããã³ãã¿
ãŒã«ã§éº»é ããŠåµå·£åé€ãããåå®®ãæåºãã
ïŒãïŒæ¥åã«ããã®åç©ã«è¡éº»æ²¹0.2mlã«æº¶è§£
ããããšã¹ãã©ãžãªãŒã«ãã³ãŸãšãŒã10ÎŒïœã
æ¯æ¥ç®äžæ³šå°ããããã®åç©ã麻é ã«ãããã
ã€é éèã«ãã€ãŠçè¡ãããåå®®ãæåºããã
ã€å·ããé£å¡©æ°Žã§æŽæµããã 现è質ãŸã«ã®è£œé å šãŠã®åŸç¶ã®å·¥çšãïŒâã®å·ãã宀ã®äžã§å®
æœãããåå®®ããççæ§èèªçµç¹ãåãé€ãã
ãã®åå®®ãæž©åã«æŽæµããè¡ç®¡ããæ®åãã幟
ããã®è¡æ¶²ãé€å»ããããã®åå®®çµç¹ïŒïœã
EDTA1.5Ã10-3ã¢ã«ïŒåã³ã°ãªã»ããŒã«30
ïŒ ã嫿ãã0.01ã¢ã«ïŒããªã¹ç·©è¡æ¶²ïŒmlã
PH7.5ãäžã«å ¥ãããã€éã¿ã§å°çã«è£æããã
ãã®çµç¹ããŠã«ãã©âã¿ãŒã©ãã¯ã¹ïŒUltraâ
TurraxïŒïŒJanke u.Kunkel瀟ããã€ãåšïŒã
çšããŠå質åãããã€ç·©è¡æ¶²ïŒmlåœãçµç¹ïŒïœ
ã®æçµæ¿åºŠã«ãŸã§ç·©è¡æ¶²ã§æŽæµãããé å¿åé¢
管ã«ç§»ããããã®å質ç©è³ªããœã«ãã«
ïŒSorvallïŒé å¿åé¢åšäžã§1000Ãïœã§10åéé
å¿åé¢ããããŸããäžæŸã¿æ¶²ãããã¯ãã³
ïŒBeckmanïŒé å¿åé¢åšãååŒïŒ¬ ïŒâ50äžã§
105000Ãïœã§90åéé å¿åé¢ãããèèªå±€ã®äž
ã®äžæŸã¿æ¶²ãæéãããã€â18âã§è²¯èµããã ææž©ä¿æ ãã®ã€ã©ã®è©äŸ¡åæã®åã«ãå宮现è質ãŸã«
ãã³ã«ããŸãŒã«ã§åŠçãããã©ã³ã¹ã³ã«ãã³ã®
çµåéšäœã飜åããããã³ã«ããŸãŒã«10ÎŒ
ïŒ10-4ã¢ã«ïŒïŒã现è質ãŸã«0.4mlã«æ·»å ãã
ãã€ïŒâã§15åéä¿æããã 3Hâããã²ã¹ããã³10ÎŒïŒæçµæ¿åºŠ10-7ã¢
ã«ïŒïŒããã³æšæºæ²ç·ã®ããã«æšèåãããŠ
ããªãããã²ã¹ããã³10ÎŒãŸãã¯é©åœãªæ¿åºŠ
ã®è©Šéšç©è³ª10ÎŒã现è質ãŸã«20ÎŒã«æ·»å ã
ããã¹ããã€ãããæçµæ¿åºŠãïŒïŒ ãäžå»»ããª
ããããªçšåºŠã«ãšã¿ããŒã«ã«æº¶è§£ãããåžéã®
ããã®ç·©è¡æ¶²ã¯ãã°ãªã»ããŒã«10ïŒ ã®ã¿ã嫿
ããŠããããã®ã€ã©è©ŠæãïŒâã§60åéææž©ä¿
æãããææž©ä¿æåŸãã°ãªã»ããŒã«10ïŒ ãæã
ãç·©è¡æ¶²0.46mlãæ·»å ãã0.2mlã®ã¢ãªã³ãŒã
ãã«ã©ã äžã«æœããã ã»ãã¢ããã¯ã¹ïŒ§â10ã«ã©ã äžã§ã®åé¢ ã»ãã¢ããã¯ã¹ïŒ§â10ããEDTA1.5Ã10-3
ã¢ã«ïŒåã³ã°ãªã»ããŒã«10ïŒ ã嫿ãã10-2
ã¢ã«ïŒããªã¹ç·©è¡æ¶²ãPH7.5ãäžã«æžæ¿ãã
ããä»ã«ã¯äœãåããŠããªãç³è±ç¶¿æ¯ã®å°ããª
æ ãæãã容ç©çŽïŒmlã®ãã¹ããŒã«åŸ®é管ãã«
ã©ã ãšããŠäœ¿çšãããå ã®è©Šéšã«ãããããã²
ã¹ããã³ãçµåããå容äœã¯ç·©è¡æ¶²ïŒmlã§æº¶é¢
ãããããšã倿ãããçµåããŠããªãããã²
ã¹ããã³ãç·©è¡æ¶²ãšã¡ã¿ããŒã«ãšã®æ··åç©ïŒml
ïŒïŒïŒïŒãïœïŒïœïŒãçšããŠã«ã©ã ããå®éç
ã«æŸåºããã æº¶åºæ¶²ã®å®¹éãç·©è¡æ¶²ïŒã¡ã¿ããŒã«ã§èª¿ç¯ã
ãåŸãæŸå°èœãæ¶²äœã·ã³ãã¬ãŒã·ãšã³èšæ°åšäž
ã§ã€ã³ã¹ã¿ã²ã«ïŒInstagelïŒäžã®åæ¹ã®ç»å
ã®å Žåã«ã€ããŠèšæ°ããã ä»ã®ããã²ã¹ããŒã²ã³ã®çžå¯ŸççµåèŠªåæ§ã
枬å®ããããã«ã 3Hâããã²ã¹ããã³ãšã
æšèåãããŠããªãç©è³ªãšã®å€äœã察æ°ã¢ã«æ¿
床ã«å¯ŸããçŸåçã§ã®çµåãšããŠããããã
ãããã®ãããªå€äœæ²ç·ã¯ãããžãã察æ°å€æ
ã«ãã€ãŠç·ç¶åããããšãã§ãããååç©ã®æŽ»
æ§ã¯ãããã²ã¹ããã³ãšç䟡ã®å€äœãåŸããã
ã®æ¿åºŠã®åæ°ãšèŠå®ãããŠããç«¶åçãã¢ã¯ã¿
ãŒãšããŠç€ºãããã ïŒ ã©ããåç«è ºã®çްè質ãŸã«äžã®ç·æ§ãã«ã¢ã³
åå®¹äœ ã©ããåç«è ºã®ãã¢ã²ããŒãã®çްè質ãŸã«
ã¯ãèçœè³ªãå容äœååã嫿ãããã®å容äœ
ååã¯ãé«ãèŠªåæ§åã³äœãèœåãæãããžã
ãããã¹ãã¹ããã³ïŒDHTïŒãçµåãããã
ã®å容äœãæšèåãããŠããªãåæç·æ§ãã«ã¢
ã³ã®ååšäžã« 3Hâãžããããã¹ãã¹ããã³ãš
äžç·ã«ææž©ä¿æããå Žåã«ã¯ãç¹åŸŽã®ããæäž
éã«äŸåããå€äœæ²ç·ãåŸãããããã®æ§è³ª
ã¯ãæ°èŠååç©ã®äžè¬çãªèšèŒã«ãšã€ãŠå¥œé©ãª
ãã®ã§ããã ç©è³ªïŒ 60CiïŒããªã¢ã«ã®ç¹ç°ç掻éãæãã5αâ
ãžãããâ1αïŒ2αâ 3HïŒïœïŒïŒœâãã¹ãã¹ãã
ã³ã¯ãè±åœã®ã¢ã¡ã«ã·ã€ã 瀟ïŒAmershamïŒ
ããå ¥æã§ããã»ãã¢ããã¯ã¹ïŒïŒSephadexïŒ
â10ã¯ãã¹ãŠãšãã³åœã®ãã¢ã«ãã·ã¢ç€Ÿ
ïŒPharmaciaïŒããå ¥æã§ãããä»ã®å šãŠã®ç©
質ã¯ãåæã®çšåºŠã«å¿ããŠåæ¥çã«å ¥æã§ã
ãã åç©ïŒ äœé300ã400ïœã®æçããã©ããïŒç³»çµ±ïŒ
Wistarã墿®ïŒSchering瀟ïŒããšãŒãã«ã§éº»
é ããŠåµå·£åé€ãããåµå·£ãåé€ããŠãã20ã
24æéåŸã«ããã®åç©ãæé ããã€çè¡ããã
è ºãæ°·å·åŽããã¹ã¯ããŒã¹0.25mlïŒäžã«æé
ããã 现è質ãŸã«ã®è£œé å šãŠã®åŸç¶ã®å·¥çšãïŒâã®å·ãã宀ã®äžã§å®
æœãããåç«è ºããççæ§èèªçµç¹ãåãé€
ãããã€å§æŸããè¡ç®¡ããæ®åãã幟ããã®è¡
æ¶²ãé€å»ããããã®åç«è ºçµç¹ã濟çŽäžã§ãã
ãããããã€éã¿ã§å°çã«è£æããããã®åç«
è ºçµç¹ïŒïœã0.01ã¢ã«ïŒããªã¹ç·©è¡æ¶²0.6mlã
PH7.5ãäžã«å ¥ãããã€ã¢ãªã³ãŒããããã¿ãŒ
âãšã«ãã ïŒPotterâElvehjemïŒïŒmlãšäžç·
ã«å質åããã詊æãæéãããã€ç·©è¡æ¶²ïŒml
åœãçµç¹ïŒïœã®æçµæ¿åºŠã«ãŸã§ç·©è¡æ¶²ã§åžéã
ãããã®ãã¢ã²ããŒããããã¯ãã³
ïŒBeckmanïŒé å¿åé¢åšãååŒïŒ¬ ïŒâ50äžã§
105000Ãïœã§90åéé å¿åé¢ãããèèªå±€ã®äž
ã®äžæŸã¿æ¶²ãæéãããã€â18âã§ã¢ãªã³ãŒã
ã§è²¯èµããã ææž©ä¿æ 3HâDHT10ÎŒïŒæçµæ¿åºŠïŒÃ10-8ã¢ã«ïŒ
ïŒããã³æšæºæ²ç·ã®ããã«æšèåãããŠããª
ãDHT10ÎŒãŸãã¯é©åœãªæ¿åºŠã®è©Šéšç©è³ª10ÎŒ
ã现è質ãŸã«40ÎŒã«æ·»å ãããã¹ããã€ã
ããæçµæ¿åºŠãïŒïŒ ãäžå»»ããªããããªçšåºŠã«
ãšã¿ããŒã«ã«æº¶è§£ããããã®ã€ã©è©ŠæãïŒâã§
120åéææž©ä¿æãããææž©ä¿æåŸãç·©è¡æ¶²
0.44mlãæ·»å ãã0.2mlã®ã¢ãªã³ãŒããã«ã©ã
äžã«æœããã ã»ãã¢ããã¯ã¹ïŒ§â10ã«ã©ã äžã§ã®åé¢ ã»ãã¢ããã¯ã¹ïŒ§â10ããããªã¹ç·©è¡æ¶²0.01
ã¢ã«ïŒã¢ã«ãPH7.5ãäžã«æžæ¿ããããä»ã«
ã¯äœãåããŠããªãç³è±ç¶¿æ¯ã®å°ããªæ ãæã
ã容ç©çŽïŒmlã®ãã¹ããŒã«åŸ®é管ãã«ã©ã ãšã
ãŠäœ¿çšãããå ã®è©Šéšã«ãããDHTãçµåã
ãå容äœã¯ç·©è¡æ¶²ïŒmlã§æº¶é¢ãããããšã倿
ãããçµåããŠããªãDHTãç·©è¡æ¶²ãšã¡ã¿ã
ãŒã«ãšã®æ··åç©ïŒmlïŒïŒïŒïŒãïœïŒïœïŒãçšã
ãŠã«ã©ã ããå®éçã«æŸåºããã æº¶åºæ¶²ã®å®¹éãç·©è¡æ¶²ïŒã¡ã¿ããŒã«ã§èª¿ç¯ã
ãåŸãæŸå°èœãæ¶²äœã·ã³ãã¬ãŒã·ãšã³èšæ°åšäž
ã§ã€ã³ã¹ã¿ã²ã«ïŒInstagelïŒäžã®åæ¹ã®ç»å
ã®å Žåã«ã€ããŠèšæ°ããã ä»ã®æŸå°èœã¹ããã€ãã®çžå¯ŸççµåèŠªåæ§ã
枬å®ããããã«ãæšèåãããŠããªãç©è³ªã«ã
ã 3HâDHTã®å€äœã察æ°ã¢ã«æ¿åºŠã«å¯Ÿã
ãçŸåçã§ã®çµåãšããŠããããããããã®ã
ããªå€äœæ²ç·ã¯ããããããŒãïŒRodbardïŒä»
ã«ããããžããïŒå¯Ÿæ°å€æã«ãã€ãŠç·ç¶åãã
ããšãã§ããïŒJ.Lab.Clin.Med.74ïŒ770ã
1969ïŒãç«¶åçãã¢ã¯ã¿ãŒïŒKFïŒã¯ã詊éšè©Šæ
ã®æ¿åºŠãšãåºæºç©è³ªïŒããªãã¡ãDHTïŒã®æ¿
床ãšã®å²åãšããŠèŠå®ãããã ä»ã®ç·æ§ãã«ã¢ã³ã®çžå¯ŸççµåèŠªåæ§ãæž¬å®
ããããã«ã 3Hâãžããããã¹ãã¹ããã³
ãšãæšèåãããŠããªãç©è³ªãšã®å€äœã察æ°ã¢
ã«æ¿åºŠã«å¯ŸããçŸåçã§ã®çµåãšããŠãããã
ããããã®ãããªå€äœæ²ç·ã¯ãããžãã察æ°å€
æã«ãã€ãŠç·ç¶åããããšãã§ãããååç©ã®
掻æ§ã¯ããžããããã¹ãã¹ããã³ãšç䟡ã®å€äœ
ãåŸãããã®æ¿åºŠã®åæ°ãšèŠå®ãããŠããç«¶å
çãã¢ã¯ã¿ãŒãšããŠç€ºãããã
ã衚ã
RïŒãšãã«ïŒCïŒïŒïŒCïŒ
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒïŒïŒïŒ åŒäžãR1ã¯æ°ŽçŽ åååã¯ã¡ãã«åºã衚ããã
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯ãåŒãåºå㯠ãåŒãåºã衚ããã ã¯ã«ã«ããã«åºã衚ããããã€ç¬¬ïŒåã³ç¬¬ïŒ
ã®ççŽ ååéã®çµåã¯ã飜åãããŠãããåã¯äº
éçµåã§ããã§ç€ºããã7αâã¢ã«ã³ãã·ã«ã«
ããã«â15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹
ãã³ååç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒ
âã¢ã³ããã¹ãã³â17αâã€ã«ïŒããããªã³é žã©
ã¯ãã³ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åå
ç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒ
âã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒããããªã³
é žã©ã¯ãã³ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
ååç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒïŒ
ïŒâã¢ã³ããã¹ã¿ãžãšã³â17αâã€ã«ïŒããããª
ã³é žã®ã«ãªãŠã å¡©ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®ååç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒ
âãªããœâïŒâã¢ã³ããã¹ãã³â17αâã€ã«ïŒã
ãããªã³é žã©ã¯ãã³ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®ååç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â6αâã¡ãã«â15βïŒ16βâã¡ãã¬ã³âïŒ
âãªããœâïŒïŒïŒâã¢ã³ããã¹ã¿ãžãšã³â17αâ
ã€ã«ïŒããããªã³é žã©ã¯ãã³ã§ãããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒâïŒ7αâã¡ããã·ã«ã«ããã«â17βâãã
ããã·â15βïŒ16βâã¡ãã¬ã³âïŒâãªããœâïŒ
âã¢ã³ããã¹ã¿ãã³â17αâã€ã«ïŒããããªã³é ž
ã®ã«ãªãŠã å¡©ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®ååç©ã ïŒ äžè¬åŒïŒïŒïŒ åŒäžãR1ã¯æ°ŽçŽ åååã¯ã¡ãã«åºã衚ããã
R2ã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
衚ããã ã¯ãåŒãåºå㯠ãåŒãåºã衚ããã ã¯ã«ã«ããã«åºã衚ããããã€ç¬¬ïŒåã³ç¬¬ïŒ
ã®ççŽ ååéã®çµåã¯ã飜åãããŠãããåã¯äº
éçµåã§ããã§ç€ºããã7αâã¢ã«ã³ãã·ã«ã«
ããã«â15βïŒ16βâã¡ãã¬ã³âïŒâã¢ã³ããã¹
ãã³ååç©ã®è£œé æ³ã«ãããŠãèªäœå ¬ç¥ã®æ¹æ³
ã§ãäžè¬åŒïŒïŒïŒ åŒäžãR1ã¯åèšã®ãã®ã衚ããã§ç€ºããã
ååç©ãåå¿ãããŠäœçŽã¢ã«ãã«âãšã¹ãã«ã«å€
ããå Žåã«ãã€ãŠã¯Î1âäºéçµåãå°å ¥ãå
ã³ïŒåã¯ã©ã¯ãã³ç°ãçžåœããããããªã³é žâã«
ãªãŠã å¡©ã«éç°ããããšãç¹åŸŽãšãããäžè¬åŒ
ïŒïŒã®7αâã¢ã«ã³ãã·ã«ã«ããã«â15βïŒ16βâ
ã¡ãã¬ã³âïŒâã¢ã³ããã¹ãã³ååç©ã®è£œé æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813111951 DE3111951A1 (de) | 1981-03-23 | 1981-03-23 | 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57177000A JPS57177000A (en) | 1982-10-30 |
| JPH0411558B2 true JPH0411558B2 (ja) | 1992-02-28 |
Family
ID=6128363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57046179A Granted JPS57177000A (en) | 1981-03-23 | 1982-03-23 | 7 alpha-alkoxycarbonyl-15 beta, 16 beta- methylene-4-androstene compound, manufacture and medicine having cortex hormone inhibition |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4450107A (ja) |
| EP (1) | EP0061418B1 (ja) |
| JP (1) | JPS57177000A (ja) |
| AT (1) | ATE15051T1 (ja) |
| AU (1) | AU555657B2 (ja) |
| CA (1) | CA1202615A (ja) |
| DD (1) | DD202440A5 (ja) |
| DE (2) | DE3111951A1 (ja) |
| DK (1) | DK91282A (ja) |
| HU (1) | HU184516B (ja) |
| IE (1) | IE52934B1 (ja) |
| IL (1) | IL65316A (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| DE3326013A1 (de) * | 1983-07-15 | 1985-01-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-methylen-17(alpha)-pregna-4,6-dien-21-carbonsaeuresalze, diese enthaltende pharmazeutische praeparate sowie verfahren zu deren herstellung |
| DE3330084A1 (de) * | 1983-08-17 | 1985-03-07 | Schering AG, 1000 Berlin und 4709 Bergkamen | 7(alpha)-alkoxycarbonyl-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone und deren 21-carbonsaeuresalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3481707D1 (de) * | 1983-08-17 | 1990-04-26 | Schering Ag | 7-alpha-substituierte 3-oxo-17alpha-pregn-4-en-21.17-carbolactone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. |
| DE3414508A1 (de) * | 1984-04-13 | 1985-10-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrfach tritiierte steroid-20.17-spirolactone und ihre verwendung als tracersubstanzen |
| ES2053091T3 (es) * | 1989-08-04 | 1994-07-16 | Schering Ag | 16alfa,17beta-metilen-estra-4,9-dien-3-onas sustituidas en 11beta. |
| WO2008109719A2 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Steroids derivatives as selective progesterone receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787940A (fr) * | 1971-08-25 | 1973-02-26 | Searle & Co | Nouveaux medicaments diuretiques et hypotenseurs et procede de leur preparation |
| GB1368006A (en) * | 1972-08-24 | 1974-09-25 | Searle & Co | 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone |
| IE44711B1 (en) * | 1976-03-05 | 1982-03-10 | Schering Ag | 17 -hydroxypropyl-4-3-keto-steroids and esters thereof, and process for their manufacture |
| DE2652761C2 (de) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US4069219A (en) * | 1976-12-27 | 1978-01-17 | G. D. Searle & Co. | 7Ο-(Alkoxycarbonyl)-6Ο-alkyl/halo-17-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactones and corresponding 21-carboxylic acids, their salts, and esters |
| DE2922500A1 (de) * | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
-
1981
- 1981-03-23 DE DE19813111951 patent/DE3111951A1/de not_active Withdrawn
-
1982
- 1982-03-03 DK DK91282A patent/DK91282A/da not_active Application Discontinuation
- 1982-03-19 DE DE8282730038T patent/DE3265533D1/de not_active Expired
- 1982-03-19 EP EP82730038A patent/EP0061418B1/de not_active Expired
- 1982-03-19 AT AT82730038T patent/ATE15051T1/de not_active IP Right Cessation
- 1982-03-19 DD DD82238302A patent/DD202440A5/de unknown
- 1982-03-22 HU HU82851A patent/HU184516B/hu not_active IP Right Cessation
- 1982-03-22 CA CA000399045A patent/CA1202615A/en not_active Expired
- 1982-03-23 IE IE669/82A patent/IE52934B1/en unknown
- 1982-03-23 AU AU81810/82A patent/AU555657B2/en not_active Ceased
- 1982-03-23 IL IL65316A patent/IL65316A/xx unknown
- 1982-03-23 US US06/361,164 patent/US4450107A/en not_active Expired - Fee Related
- 1982-03-23 JP JP57046179A patent/JPS57177000A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ATE15051T1 (de) | 1985-09-15 |
| US4450107A (en) | 1984-05-22 |
| DE3111951A1 (de) | 1982-09-30 |
| CA1202615A (en) | 1986-04-01 |
| EP0061418A1 (de) | 1982-09-29 |
| DK91282A (da) | 1982-09-24 |
| JPS57177000A (en) | 1982-10-30 |
| HU184516B (en) | 1984-09-28 |
| IE52934B1 (en) | 1988-04-13 |
| IL65316A0 (en) | 1982-05-31 |
| EP0061418B1 (de) | 1985-08-21 |
| IL65316A (en) | 1985-05-31 |
| IE820669L (en) | 1982-09-23 |
| DE3265533D1 (en) | 1985-09-26 |
| AU555657B2 (en) | 1986-10-02 |
| AU8181082A (en) | 1982-09-30 |
| DD202440A5 (de) | 1983-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2588267B2 (ja) | ïŒïŒïŒïŒïŒÎ²âæ¶æ©ã¹ããã€ãïŒãã®è£œé æ³ããã³è©²ååç©ã嫿ãã補è¬åŠçèª¿å€ | |
| US5565588A (en) | 9-alpha-hydroxy steroids, process for their preparation, process for the preparation of the corresponding 9(11)-dehydro derivatives and pharmaceutical preparations containing said steroids | |
| Eriksson et al. | Steroids in Germfree and Conventional Rats: 4. Identification and Bacterial Formation of 17뱉Pregnane Derivatives | |
| DK162101B (da) | 11beta-(4-isopropenylphenyl)-oestra-4,9-diener, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse forbindelser samt anvendelsen af forbindelserne til fremstilling af laegemidler | |
| JPH07316185A (ja) | ïŒïŒäœçœ®ã«çœ®æåºãæã€æ°ã¹ããã€ãã®è£œé çšäžéäœ | |
| US2878247A (en) | Preparation of 6-methyl steroids of the pregnane series | |
| US4013688A (en) | Radioimmunoassay agents | |
| US4701449A (en) | Novel 10-substituted steroids and their use in the induction of aldosterone antagonistic activity | |
| EP1831239B1 (en) | A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid lambda-lactone and key-intermediates for this process | |
| AU5819694A (en) | New steroids | |
| JP5399711B2 (ja) | é«çŽåºŠãªïŒïŒÎ±âã·ã¢ãã¡ãã«âïŒïŒÎ²âããããã·âãšã¹ãã©âïŒïŒïŒâãžãšã³âïŒâãªã³åã³ãã®åææ¹æ³ | |
| JPH0372080B2 (ja) | ||
| HUP0402465A2 (en) | Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process | |
| DE69215125T2 (de) | Kardioaktive Steroide | |
| JPH08502276A (ja) | ã²ã¹ã¿ãŒã²ã³äœçšãæããïŒïŒïŒïŒïŒâæ¶æ©ããïŒâãšã¹ãã¬ã³ | |
| Kamata et al. | Aldosterone antagonists. 2. Synthesis and biological activities of 11, 12-dehydropregnane derivatives | |
| US3470160A (en) | 15,16 beta-methylene steroids of the estrane and androstane series and methods for preparing same | |
| LÅkÅs et al. | Steroids 48. Synthesis of 16α-ethyl-21-hydroxy-19-norpregn-4-ene-3, 20-dione from 17-substituted 3-methoxyestradiols | |
| JPS6044318B2 (ja) | ã¹ããã€ãã«ãïŒïŒïœïŒïŒïŒâïœãããã¿ãªã³é¡ã®è£œæ³ | |
| JPS5970700A (ja) | ïŒÎ±âã¢ã«ãã«âïŒïŒÎ±âãã¬ã°ã³âïŒâãšã³âïŒïŒïŒïŒïŒâã«ã«ãã©ã¯ãã³åã³âïŒïŒâã«ã«ãã³é žå¡©ããã®è£œæ³äžŠã³ã«è©²ååç©ã嫿ããæã¢ã«ãã¹ããã³äœçšãæãã補è¬çè£œå€ | |
| US4152325A (en) | Novel steroids and their use | |
| Mills et al. | Steroids. CXLIV. Synthesis of some 6α, 17α-dihaloprogesterones | |
| Mappus et al. | Synthesis and characterization by 1H and 13C nuclear magnetic resonance spectroscopy of 17α-cyano, 17α-aminomethyl, and 17α-alkylamidomethyl derivatives of 5α-dihydrotestosterone and testosterone | |
| Templeton et al. | Synthesis and structure-activity relationships of 14β-hydroxy-5α-pregnanes: pregnanes that bind to the cardiac glycoside receptor | |
| DD242410C4 (de) | Verfahren zur herstellung von 7 alpha-substituirten 3-oxo-17 alpha-pregn-4-en -21.17-carbolactonen |